Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.63 |
| ▸ | LTB4R | Q15722 | 8/20 | 0.61 |
| ▸ | LTB4R2 | Q9NPC1 | 8/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | GCK | P35557 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10148418 | 1.00 | KMT2A (0.65) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL8782592 | 1.00 | KMT2A (0.65) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL14967524 | 0.93 | KMT2A (0.59) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL14966382 | 0.93 | KMT2A (0.59) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL9641672 | 0.88 | LTB4R (0.63) | SRD5A2LTB4RLTB4R2FFAR1ALOX5 | |
| SCHEMBL27783533 | 0.87 | KDM4E (0.58) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL14967103 | 0.86 | KMT2A (0.61) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL11087557 | 0.86 | LTB4R (0.58) | KMT2ASRD5A2LTB4RLTB4R2FFAR1 | |
| SCHEMBL29523345 | 0.85 | LTB4R (0.57) | KMT2ALTB4RLTB4R2FFAR1ALOX5 | |
| SCHEMBL29523814 | 0.85 | LTB4R (0.57) | KMT2ALTB4RLTB4R2FFAR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | KMT2A 441/4885SRD5A2 1818/4885LTB4R 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.